About Illumina, Inc.
https://www.illumina.comIllumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
CEO
Jacob Thaysen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-09-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 533
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Guggenheim
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Stephens & Co.
Overweight
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:156.3M
Value:$22.5B
CAPITAL WORLD INVESTORS
Shares:19.98M
Value:$2.88B
BLACKROCK, INC.
Shares:18.69M
Value:$2.69B
Summary
Showing Top 3 of 1,104
About Illumina, Inc.
https://www.illumina.comIllumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.08B ▲ | $501M ▲ | $150M ▼ | 13.85% ▼ | $0.98 ▼ | $337M ▼ |
| Q2-2025 | $1.06B ▲ | $481M ▼ | $235M ▲ | 22.19% ▲ | $1.49 ▲ | $399M ▲ |
| Q1-2025 | $1.04B ▼ | $519M ▼ | $131M ▼ | 12.58% ▼ | $0.82 ▼ | $276M ▼ |
| Q4-2024 | $1.1B ▲ | $553M ▲ | $187M ▼ | 16.94% ▼ | $1.18 ▼ | $283M ▼ |
| Q3-2024 | $1.08B | $4M | $705M | 65.28% | $4.43 | $826M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.28B ▲ | $6.18B ▲ | $3.8B ▼ | $2.38B ▲ |
| Q2-2025 | $1.16B ▼ | $6.09B ▼ | $3.83B ▲ | $2.26B ▼ |
| Q1-2025 | $1.24B ▲ | $6.18B ▼ | $3.81B ▼ | $2.37B ▼ |
| Q4-2024 | $1.22B ▲ | $6.3B ▲ | $3.93B ▲ | $2.37B ▲ |
| Q3-2024 | $939M | $6.01B | $3.89B | $2.13B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $150M ▲ | $284M ▲ | $-51M ▼ | $-115M ▲ | $116M ▲ | $260M ▲ |
| Q2-2025 | $-131M ▼ | $234M ▼ | $-49M ▲ | $-371M ▼ | $-179M ▼ | $211M ▲ |
| Q1-2025 | $131M ▼ | $240M ▼ | $-63M ▼ | $-195M ▼ | $-14M ▼ | $201M ▼ |
| Q4-2024 | $187M ▼ | $364M ▲ | $-48M ▼ | $-47M ▲ | $258M ▲ | $335M ▲ |
| Q3-2024 | $704M | $316M | $-41M | $-332M | $-51M | $284M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Microarray | $90.00M ▲ | $90.00M ▲ | $90.00M ▲ | $80.00M ▼ |
 Sequencing | $990.00M ▲ | $950.00M ▼ | $970.00M ▲ | $1.00Bn ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas | $590.00M ▲ | $590.00M ▲ | $570.00M ▼ | $610.00M ▲ |
 Asia Pacific | $110.00M ▲ | $100.00M ▼ | $110.00M ▲ | $110.00M ▲ |
 CHINA | $80.00M ▲ | $60.00M ▼ | $70.00M ▲ | $50.00M ▼ |
 EMEA | $330.00M ▲ | $310.00M ▼ | $290.00M ▼ | $310.00M ▲ |
CEO
Jacob Thaysen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-09-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 533
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Guggenheim
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Stephens & Co.
Overweight
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:156.3M
Value:$22.5B
CAPITAL WORLD INVESTORS
Shares:19.98M
Value:$2.88B
BLACKROCK, INC.
Shares:18.69M
Value:$2.69B
Summary
Showing Top 3 of 1,104